Wallbox N.V. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Wallbox N.V. on December 19, 2024, covering events occurring in November and December 2024. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance data.
Material Changes
- NYSE Non-Compliance Notice: On November 21, 2024, the Company was notified by the NYSE that it failed to meet Section 802.01C of the NYSE Listed Company Manual.
- Reason for Non-Compliance: The average closing price of the Company's Class A ordinary shares fell below $1.00 over a consecutive 30 trading-day period.
- Current Status: The Class A Shares remain listed and traded on the NYSE during the cure period, subject to compliance with other listing standards.
Guidance, Outlook, and Risks
- Cure Plan: On December 2, 2024, the Company notified the NYSE of its intent to cure the deficiency. The Company has a six-month period from the date of the notice to regain compliance.
- Compliance Criteria: To cure the deficiency, the Company must achieve a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of any calendar month within the cure period.
- Shareholder Approval: If the cure action requires shareholder approval, the price condition is deemed cured if the price promptly exceeds $1.00 and remains above that level for at least 30 trading days.
- Risks: The filing includes forward-looking statements regarding the ability to regain compliance. Actual results may differ due to risks outlined in the Company's Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the current trading price of Wallbox N.V. Class A shares to assess proximity to the $1.00 threshold.
- Monitor the Company's progress within the six-month cure period to avoid potential delisting.
- Review the Company's Annual Report on Form 20-F for detailed risk factors and historical financial performance not included in this filing.
- Check for future announcements regarding specific actions (e.g., reverse stock split) intended to cure the share price deficiency.